Thus, our research suggests that pharmacological blocking of the CXCL12/CXCR4 axis can reduce megakaryocyte chemotaxis to damaged lung tissues, ultimately partially mitigating lung fibrosis. Here, CXCL12 is linked to pulmonary fibrosis.